Stock Track | Iovance Biotherapeutics Plummets 6.32% as Chardan Slashes Price Target

Stock Track

11/07

Shares of Iovance Biotherapeutics, Inc. (IOVA) plummeted 6.32% in early trading on Friday, following a significant price target cut by Chardan Capital Markets. The biotech company's stock took a hit after Chardan lowered its price target from $20 to $17, representing a 15% reduction.

Despite the price target cut, Chardan maintained its "Buy" rating on Iovance Biotherapeutics, indicating a continued belief in the company's long-term potential. However, investors appeared to focus more on the near-term implications of the lowered price target, triggering the sharp decline in IOVA's stock price.

The move comes amid a mixed analyst landscape for Iovance Biotherapeutics. According to FactSet, the average analyst rating for IOVA remains "overweight," with a mean price target of $7.75. The significant disparity between Chardan's new target and the average target highlights the wide range of opinions among analysts regarding the company's future prospects. As the trading session progresses, market participants will be closely watching how this news continues to impact IOVA's stock performance.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1126022241"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1126022241\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1126022241?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 23:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126022241","market":"sg","top_or_hot":-1,"title":"Stock Track | Iovance Biotherapeutics Plummets 6.32% as Chardan Slashes Price Target","media":"Stock Track","content":"<p>Shares of Iovance Biotherapeutics, Inc. (IOVA) plummeted 6.32% in early trading on Friday, following a significant price target cut by Chardan Capital Markets. The biotech company's stock took a hit after Chardan lowered its price target from $20 to $17, representing a 15% reduction.</p>\n\n<p>Despite the price target cut, Chardan maintained its \"Buy\" rating on Iovance Biotherapeutics, indicating a continued belief in the company's long-term potential. However, investors appeared to focus more on the near-term implications of the lowered price target, triggering the sharp decline in IOVA's stock price.</p>\n\n<p>The move comes amid a mixed analyst landscape for Iovance Biotherapeutics. According to FactSet, the average analyst rating for IOVA remains \"overweight,\" with a mean price target of $7.75. The significant disparity between Chardan's new target and the average target highlights the wide range of opinions among analysts regarding the company's future prospects. As the trading session progresses, market participants will be closely watching how this news continues to impact IOVA's stock performance.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Iovance Biotherapeutics Plummets 6.32% as Chardan Slashes Price Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Iovance Biotherapeutics Plummets 6.32% as Chardan Slashes Price Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-07 23:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Iovance Biotherapeutics, Inc. (IOVA) plummeted 6.32% in early trading on Friday, following a significant price target cut by Chardan Capital Markets. The biotech company's stock took a hit after Chardan lowered its price target from $20 to $17, representing a 15% reduction.</p>\n\n<p>Despite the price target cut, Chardan maintained its \"Buy\" rating on Iovance Biotherapeutics, indicating a continued belief in the company's long-term potential. However, investors appeared to focus more on the near-term implications of the lowered price target, triggering the sharp decline in IOVA's stock price.</p>\n\n<p>The move comes amid a mixed analyst landscape for Iovance Biotherapeutics. According to FactSet, the average analyst rating for IOVA remains \"overweight,\" with a mean price target of $7.75. The significant disparity between Chardan's new target and the average target highlights the wide range of opinions among analysts regarding the company's future prospects. As the trading session progresses, market participants will be closely watching how this news continues to impact IOVA's stock performance.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IOVA","symbol_name":"Iovance Biotherapeutics, Inc.","start_time":0,"source_url":"","article_id":"1126022241","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126022241","pubTimestamp":1762527781,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Iovance Biotherapeutics, Inc. (IOVA) plummeted 6.32% in early trading on Friday, following a significant price target cut by Chardan Capital Markets. The biotech company's stock took a hit...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IOVA":"Iovance Biotherapeutics, Inc."},"translate_title":"股票追踪|Chardan下调目标价，Iovance Biotherapeutics暴跌6.32%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IOVA":1},"content_text":"Shares of Iovance Biotherapeutics, Inc. (IOVA) plummeted 6.32% in early trading on Friday, following a significant price target cut by Chardan Capital Markets. The biotech company's stock took a hit after Chardan lowered its price target from $20 to $17, representing a 15% reduction.\nDespite the price target cut, Chardan maintained its \"Buy\" rating on Iovance Biotherapeutics, indicating a continued belief in the company's long-term potential. However, investors appeared to focus more on the near-term implications of the lowered price target, triggering the sharp decline in IOVA's stock price.\nThe move comes amid a mixed analyst landscape for Iovance Biotherapeutics. According to FactSet, the average analyst rating for IOVA remains \"overweight,\" with a mean price target of $7.75. The significant disparity between Chardan's new target and the average target highlights the wide range of opinions among analysts regarding the company's future prospects. As the trading session progresses, market participants will be closely watching how this news continues to impact IOVA's stock performance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}